2026-04-29T07:35:49Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/180252024-09-21T22:30:30Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Moriczi, Melinda author Pujol-Muncunill, Gemma author Martín-Masot, Rafael author Jiménez Treviño, Santiago author Segarra Cantón, Oscar author Ochoa Sangrador, Carlos author Peña Quintana, Luis author González Santana, Daniel author Rodríguez Martínez, Alejandro author Rosell Camps, Antonio author Armas, Honorio author Barrio, Josefa author González de Caldas, Rafael author Rodríguez Salas, Mónica author Balmaseda Serrano, Elena author Donat Aliaga, Ester author Bodas Pinedo, Andrés author Vaquero Sosa, Esther author Vecino López, Raquel author Solar Boga, Alfonso author Moreno Álvarez, Ana author Sánchez Sánchez, César author Tolín Hernani, Mar author Gutiérrez Junquera, Carolina author Martinón Torres, Nazareth author Leis Trabazo, María Rosaura author Eizaguirre, Francisco Javier author García Peris, Mónica author Medina Benítez, Enrique author Fernández Caamaño, Beatriz author Vegas Álvarez, Ana María author Crespo Valderrábano, Laura author Alonso Vicente, Carmen author Rubio Santiago, Javier author Galera-Martínez, Rafael author García-Romero, Ruth author Ros Arnal, Ignacio author Fernández Cebrián, Santiago author Lorenzo Garrido, Helena author Viada Bris, Javier Francisco author Velasco Rodríguez-Belvis, Marta author Bartolomé Porro, Juan Manuel author Blanco Rodríguez, Miriam author Barros García, Patricia author Botija, Gonzalo author Chicano Marín, Francisco José author La Orden Izquierdo, Enrique author Crehuá-Gaudiza, Elena author Navas-López, Víctor Manuel author Martín-de-Carpi, Javier author 2020-04-07 Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing in children with Crohn´s disease (CD) without the adverse effects of these drugs. The aims of this study were to determine the efficacy of EEN in terms of inducing clinical remission in children newly diagnosed with CD, to describe the predictive factors of response to EEN and the need for treatment with biological agents during the first 12 months of the disease. We conducted an observational retrospective multicentre study that included paediatric patients newly diagnosed with CD between 2014-2016 who underwent EEN. Two hundred and twenty-two patients (140 males) from 35 paediatric centres were included, with a mean age at diagnosis of 11.6 ± 2.5 years. The median EEN duration was 8 weeks (IQR 6.6-8.5), and 184 of the patients (83%) achieved clinical remission (weighted paediatric Crohn's Disease activity index [wPCDAI] 15 mg/L and ileal involvement tended to respond better to EEN. EEN administered for 6-8 weeks is effective for inducing clinical remission. Due to the high response rate in our series, EEN should be used as the first-line therapy in luminal paediatric Crohn's disease regardless of the location of disease and disease activity. http://hdl.handle.net/10668/15349 http://hdl.handle.net/20.500.12105/18025 32272604 10.3390/nu12041012 2072-6643 Nutrients Crohn’s disease calprotectin children exclusive enteral nutrition inflammatory bowel disease paediatric Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP.